NCT07530549尚未招募2 期
Iparomlimab and Tuvonralimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy: a Prospective, Single-arm, Multicenter, Phase II Clinical Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences0 个研究点目标入组 40 人开始时间: 2026年4月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
- 主要终点
- Event-free Survival(EFS)
研究概览
简要总结
The goal of this clinical trial is Iparomlimab and tuvonralimab (QL1706) combined with chemoradiotherapy in the treatment of locally advanced esophageal cancer after failed neoadjuvant chemoimmunotherapy. The main question it aims to answer is： Can it bring survival benefits and safet to patients？Subsequent evaluation will determine whether the patient undergoes surgical treatment. Follow-up will be conducted to assess the efficacy and safety of the treatment。
详细描述
Participants were treated with QL1706 and radical CCRT.After receiving the combination of QL1706 with radical CCRT, patients who are eligible for surgery will undergo the procedure, while those who are not candidates for surgery may receive sequential boost radiotherapy to PGTV at a about dose of 60 Gy. Following radiotherapy, maintenance treatment with immunotherapy combined with chemotherapy will be administered for up to one year, until disease progression, death, or the occurrence of intolerable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 years, male or female;
- •Histologically confirmed locally advanced squamous cell carcinoma or adenocarcinoma of the esophagus or esophagogastric junction;
- •ECOG performance status 0-1; ④ Failure of or local progression after 2-4 cycles of first-line chemotherapy combined with immunotherapy, or deemed unresectable by surgical evaluation;
- •⑤ At least one measurable lesion according to RECIST v1.1 criteria;
- •⑥ Adequate major organ and bone marrow function: Hematology: Hemoglobin (Hb) ≥90 g/L (without transfusion within 14 days); Absolute neutrophil count (NEUT) ≥1.5×10⁹/L; Platelets (PLT) ≥100×10⁹/L; Biochemistry: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN in cases of liver metastases); Total bilirubin (TBIL) ≤2×ULN; Serum albumin (ALB) ≥28 g/L; Serum creatinine (Cr) ≤1.5×ULN and creatinine clearance >50 μmol/L; Coagulation: International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5×ULN (unless the subject is receiving anticoagulant therapy and INR and APTT are within the expected therapeutic range);
- •⑦ Effective contraception during the study period;
- •Voluntary participation in this study with signed informed consent and good compliance.
排除标准
- •Active bleeding or high risk of bleeding (as assessed by the investigator);
- •Patients requiring systemic anti-infective therapy;
- •Concurrent primary malignant tumors other than esophageal cancer (excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- •Presence of brainstem, leptomeningeal metastasis, spinal cord metastasis, or compression;
- •Complicated with severe cardiovascular diseases, such as uncontrolled heart failure, coronary heart disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction within the past 5 years; and complicated with other uncontrolled acute or chronic diseases;
- •Positive for human immunodeficiency virus antibody (HIVAb), active tuberculosis, active hepatitis B virus infection (HBsAg positive and HBV-DNA > 500 IU/ml or the upper limit of normal, whichever is higher), or active hepatitis C virus infection (HCV antibody positive and HCV-RNA > lower limit of detection);
- •Known allergy to any component of any study drug; known history of severe hypersensitivity reactions to other monoclonal antibodies; ⑧ Adverse reactions from prior immunotherapy not fully recovered;
- •Receiving systemic glucocorticoid therapy (excluding nasal spray, inhalation, or other topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first study drug administration;
- •⑩ Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years prior to study administration. Replacement therapies (e.g., thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatments;
- •⑪ Known history of mental illness, substance abuse, alcoholism, or drug addiction;
- •⑫ Pregnant or breastfeeding women;
- •⑬ Other conditions deemed unsuitable for participation in this study by the investigator, including but not limited to poor patient compliance, intolerance, etc.
研究组 & 干预措施
Group1
Experimental
QL1706 and radical CCRT
干预措施: QL1706 (Drug)
结局指标
主要结局
Event-free Survival(EFS)
时间窗: From enrollment to the end of monitoring at 2 years
time from treatment to disease progression, local or distant recurrence, or death
次要结局
- Overall Survival (OS)(From enrollment to the end of monitoring at 2 years)
- Progression-Free Survival(PFS)(From enrollment to the end of monitoring at 2 years)
- Adverse reaction(From the start of treatment to within 90 days after the end of treatment.)
研究者
XIN WANG
Director
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
相似试验
尚未招募
2 期
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.NCT07271602Union Hospital, Tongji Medical College, Huazhong University of Science and Technology104
招募中
2 期
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTNCT07327788Nanfang Hospital, Southern Medical University38
招募中
2 期
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell CarcinomaNCT07290010Hebei Medical University Fourth Hospital25
尚未招募
2 期
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCNCT07416058Guangdong Association of Clinical Trials61
招募中
2 期
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerNCT07315854Beijing Friendship Hospital32